Form D · Biotechnology

4Tech, Inc.

Newton, MA · CIK 0001537672

Offering snapshot reported Feb 2, 2016 · SEC filing

Reported sold
$28.9M
Offering amount: $28.9M
Investors reported
15
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 8, 2015
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$14.4M$28.9MDec 22, 2015: $26,414,543.00Dec 22, 2015Feb 2, 2016: $28,852,767.00Feb 2, 2016

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$26,414,543 → $28,852,767
  • Reported investors7 → 15

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 2, 2016Amendment$28,852,767$2,438,224vs Dec 22, 201515SEC filing
Dec 22, 2015Initial$26,414,543No comparison7SEC filing
Dec 21, 2011Initial$7,000,000No comparison5SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$194K (estimated)
Finders' fees
$0
Form D file number
021-253580

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
HitherLane Partners, LLC46604

Source: Form D, filed Feb 2, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Lawrence C Best Director
Lawrence C. Best Director
Eric Le Royer Director
Rudi Marien Director
Jan Pensaert Director
Carine Schorochoff Executive
Benjamin Tsai Director
Paul Van Den Heuvel Director
Hugo Vanerman Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
C/O Oxo Capital Llc 275 Grove Street, Suite 2 400
Newton, MA, 02466